September 8, 2023

Sirtex Collaborates With Magle Group on EmboCept S DSM 50 μm

September 8, 2023—Sirtex Medical announced a collaboration agreement with Magle Group, a Sweden-based contract development and manufacturing organization with a platform of degradable starch microspheres (DSM), for the development of new products.

Under the terms of the agreement, Sirtex will exclusively distribute Magle Group’s EmboCept S 50 μm chemoembolization product in existing and new geographic areas. The companies also intend to establish a joint development plan to increase product range in the field of embolization by utilizing Magle Group’s DSM platform.

EmboCept S DSM 50 μm is currently approved for sale in Europe, Argentina, Singapore, and Malaysia. It is indicated for chemoembolization of liver and lung tumors.

According to Sirtex, EmboCept S DSM 50 μm is an adjuvant in the intra-arterial treatment of inoperable liver and lung tumors in combination with cytostatic agents. Because of its degradability, EmboCept S can be applied for superselective treatments of single-liver segments and used for a selective targeting of one liver lobe to treat multifocal, diffuse tumors and nonvisible micro tumors.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

September 8, 2023

Sirtex Collaborates With Magle Group on EmboCept S DSM 50 μm

Current Issue

Keep In Touch